Olaratumab + Doxorubicin + Ifosfamide + Mesna
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Soft Tissue Sarcoma
Conditions
Soft Tissue Sarcoma
Trial Timeline
Oct 18, 2017 → Aug 25, 2019
NCT ID
NCT03283696About Olaratumab + Doxorubicin + Ifosfamide + Mesna
Olaratumab + Doxorubicin + Ifosfamide + Mesna is a phase 1 stage product being developed by Eli Lilly for Soft Tissue Sarcoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03283696. Target conditions include Soft Tissue Sarcoma.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03283696 | Phase 1 | Completed |
Competing Products
20 competing products in Soft Tissue Sarcoma